Overview

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Status:
Completed
Trial end date:
2016-01-11
Target enrollment:
Participant gender:
Summary
This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Contraceptive Agents
Contraceptives, Oral
Fostemsavir
Norethindrone
Norethindrone acetate
Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination
Norinyl
Progestins